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Abstract Biogenic amines such as norepinephrine, dopa-
mine, and serotonin play a well-described role in the treatment
of mood disorders especially depression. Animal models are
widely used to study antidepressant-like effect in rodents;
however, it should be taken into account that pharmacological
models do not always answer to the complexity of the disease
processes. This study verified the behavioral (forced swim test
(FST), locomotor activity test) and neurochemical effects
(monoamines metabolism) of a low dose of clonidine
(0.1 mg/kg i.p.) which was used as an experimental model
of depression. In such pharmacological model, we investigat-
ed the antidepressant-like effect of an endogenous neuropro-
tective amine, 1-methyl-1,2,3,4-tetrahydroisoquinoline
(1MeTIQ) administered in a dose of 25 mg/kg (i.p.) before
clonidine in the behavioral and neurochemical tests carried out
in rats. The behavioral study has shown that clonidine pro-
duced depression in the locomotor activity test but did not
cause pro-depressive effect in the FST. 1MeTIQ produced
antidepressant-like effect in the FST and completely antago-
nized clonidine-induced sedation in the locomotor activity
test. Neurochemical data demonstrated that clonidine pro-
duced a significant inhibition of monoamine metabolism in
the central nervous system. The release of dopamine, nor-
adrenaline, and serotonin as well as the rate of their metabo-
lism were diminished in the investigated brain structures
(frontal cortex, hypothalamus, and striatum). 1MeTIQ
completely antagonized the clonidine-induced depression of
monoaminergic systems and restored their levels to the control
values. 1MeTIQ as an endogenous neuroprotective compound
with a distinct antidepressant-like activity in rodents produces
hope on the efficiency of antidepressant medicines for future
practical clinical use.
Keywords Clonidinemodelofdepression .Forcedswimtest .
HPLC .Metabolism ofmonoamines . Brain structures . Rat
Introduction
Animal models are widely used to study antidepressant-like
effect in rodents. However, it should be mentioned that phar-
macological models do not always take into account the com-
plexity of the disease process which is thought to be multifac-
torial. What is more, despite intensive research conducted in
many scientific centers worldwide, the mechanism evoking
depression is not clear till now. It is well known that mono-
amine neurotransmitters, such as dopamine (DA), noradrena-
line (NA), and serotonin (5-HT) in the central nervous system
play a key role in the pathophysiology of depression (Mayeux
et al. 1984; Chan-Palay and Asan 1989; Elhwuegi 2004). All
commercially available antidepressants, including the tricy-
clics, monoamine oxidase (MAO) inhibitors, non-selective
adrenoceptor antagonists, and selective 5-HT reuptake inhib-
itors (SSRIs) work via various mechanisms to increase synap-
tic concentrations of monoamines (Cryan and Lucki 2000;
Mico et al. 2006; Elhwuegi 2004). The monoaminergic hy-
pothesis claims that depression is caused by a decreased
monoaminergic function of the brain. The vast body of avail-
able world literature has shown that antidepressants act mostly
on the 5-HTand NA systems (Papakostas et al. 2007). DA has
been classically associated with abuse disorders and psycho-
sis, but it may play also a role in depression. The 5-HT, NA,
and DA systems are linked by complex interactions, thus most
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of the effects exerted on 5-HT or NA systems affect DA re-
lease (Westenberg 1999; Invernizzi and Garattini 2004).
However, abnormalities in monoaminergic neurotransmis-
sion are associated with a number of neurological disorders,
like Parkinson’s disease, and as generally accepted, also psy-
chiatric disorders, like schizophrenia or depression. Although
the mechanism provoking depression has not been clearly
elucidated, however, oxidative stress associated with genera-
tion of reactive oxygen species (ROS) can be one of the main
causes in molecular processes underlying this disease.
Recently, it was shown that enhanced neurodegeneration as-
sociated with depression may be partially attributed to oxida-
tive stress and inflammation (Maes 2008; Maes et al. 2011;
Makhija and Karunakaran 2013). Therefore, other strategies
beyond monoamine (DA, NA, and 5-HT) reuptake inhibition
such as anti-oxidative agents may represent promising
antidepressant therapies. For instance, many anti-oxidant
agents have shown antidepressant-like activity in animal
models of depression (Lopresti et al. 2012; El-Naga et al.
2014; Tizabi et al. 2014).
In the present study, we analyzed the antidepressant potential
of the endogenous amine from the tetrahydroisoquinoline group,
1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) in the cloni-
dine model of depression. Our previous studies demonstrated
antidepressant-like effect of 1MeTIQ in different animal models
of depression (Antkiewicz-Michaluk et al. 2014b;Możdżeń et al.
2014; Wąsik et al. 2013). 1MeTIQ has a special position among
new investigated substances with antidepressant-like effect be-
cause it is a neuroprotective compoundwith an anti-parkinsonian
potential (Antkiewicz-Michaluk et al. 2003, 2004, 2014a;
Makino et al. 1990; Kotake et al. 1995; Tasaki et al. 1991).
Additionally, 1MeTIQ reversibly inhibited MAOA and B activ-
ities at micro-molar concentrations (Patsenka and Antkiewicz-
Michaluk 2004) and showed the ability to inhibit free radical
formation and to abolish H2O2 generation from dopamine via
the Fenton reaction (Antkiewicz-Michaluk et al. 2006). 1MeTIQ
which is present in the brain, is a mixture of (R)- and (S)-enan-
tiomers enzymatically synthesized from 2-phenylethylamine and
pyruvate by the 1MeTIQ-synthesizing enzyme, a membrane-
bound protein localized in the mitochondrial synaptosomal frac-
tion (Yamakawa and Ohta 1997; Yamakawa et al. 1999).
1MeTIQ was shown to act as an anti-dopaminergic agent, but
in contrast to typical neuroleptics, it did not induce catalepsy in
animals (Antkiewicz-Michaluk et al. 2000, 2014a). In functional
studies, 1MeTIQ inhibited an apomorphine-induced hyperactiv-
ity at doses where it had no effect on the spontaneous locomotor
activity of rats (Antkiewicz-Michaluk et al. 2001). In addition,
in vitro as well as in vivo studies have demonstrated that
1MeTIQ behaves as a partial dopamine agonist and monoamine
reuptake inhibitor (Antkiewicz-Michaluk et al. 2007; Patsenka
et al. 2004).
Presently, we examined behavioral and neurochemical ef-
fects of a low-dose clonidine (0.1 mg/kg i.p.), and then
evaluated antidepressant-like effect of 1MeTIQ in the cloni-
dine model of depression. Clonidine is an alpha2 adrenoceptor
agonist used in the treatment of hypertension. Clonidine has
been shown to produce depressive behavioral effects in labo-
ratory animals, and thus it has been suggested to be a suitable
animal model of depression (Enginar and Eroğlu 1990; Lim
et al. 2016; Parale and Kulkarni 1986; Park et al. 2016).
Behavioral forced swim test (FST) was used to examine the
antidepressant properties of 1MeTIQ. The FST is a test with
high predictive validity for antidepressant efficacy in human
depression. Recently, a behavior-sampling technique was de-
veloped that scores individual response categories, including
immobility, swimming, and climbing (Detke et al. 1995).
Selective serotonin reuptake inhibitors increase swimming be-
havior while drugs acting primarily to elevate extracellular
levels of NA or DA increase climbing behavior (Borsini
1995; Detke et al. 1995; Detke and Lucki 1996; Nixon et al.
1994). Additionally, the locomotor activity test was used to
check motor function of rats in the clonidine model of
depression.
In the second part of the study, in addition to the behavioral
tests, we also carried out neurochemical ex vivo studies to
determine the tissue concentration of monoamines as well as
the rate of their metabolism in rat brain structures (frontal
cortex, hypothalamus, and striatum).
Materials and Methods
Animals
The experiments were carried out onmaleWistar rats (Charles
River) with an initial body weight of 230–240 g (about
7 weeks old). The animals were kept under standard laborato-
ry conditions with free access to laboratory food and tap water,
at room temperature of 22 °C with an artificial day-night cycle
(12/12 h, lights on at 7 a.m.). All the procedures were carried
out in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and were granted
an approval from the Bioethics Commission as compliant with
Polish Law. The experimental protocols were approved by the
Local Bioethics Commission of the Institute of Pharmacology,
Polish Academy of Sciences in Kraków, Poland.
Drugs
1MeTIQ was synthesized in the Department of Drug
Chemistry, Institute of Pharmacology, Polish Academy of
Sciences, Krakow, Poland; the purity of the compound was
verified by measurement of the melting point, and homogene-
ity was assessed on a chromatographic column. Clonidine
(hydrochloride) was from Sigma-Aldrich (St. Louis, MO,
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USA). The drugs were dissolved in sterile 0.9%NaCl solution
and were injected in a volume of 4 ml/kg.
Behavioral Experiments
The Forced Swim Test Procedure
The studies were carried out on rats and were based on the
method of Porsolt et al. (1978). All the animals were individ-
ually tested in the FST on two consecutive days with 1 ses-
sion/day. On the first day, the rats were individually placed in
non-transparent plastic cylinders (diameter, 23 cm; height,
50 cm) containing water of a height of 30 cm, maintained at
25–26 °C. Theywere allowed to swim for 15min before being
removed (pre-test session). After, the animals were dried and
returned to their home cages. The procedure was repeated 24 h
later, and the time of the escape-oriented behavior of the rats
was recorded (for 5-min test session). The observed behavior-
al parameters (in the order of priority) were time spent floating
in water (immobility), swimming, and struggling (climbing).
According to Detke et al. (1995), the immobility is described
as the behavior of the rat when it makes only the movements
necessary to keep its head above the water. In this case, ani-
mals can make certain slight swimming movements in order
to remain afloat. Climbing is defined as vigorous movements
of four limbs, with the front paws breaking against the wall of
the cylinder. During swimming, rats make coordinated and
sustained movements (more than necessary) with all four
limbs, usually traveling around the interior of the cylinder
but without breaking the surface of the water with forelimbs.
Water was changed between subjects. The FSTwas performed
120 min after 1MeTIQ (25 mg/kg i.p.) and 60 min after clo-
nidine (0.1 mg/kg i.p.) administration. In the combined treat-
ment groups, 1MeTIQ was administered 60 min before cloni-
dine injection. Six to eight animals per group were used. The
experiments were carried out between 9 a.m. and 3 p.m.
Locomotor Activity
The locomotor activity was measured in actometers (Opto-
Varimex activity monitors, Columbus Instruments, USA)
linked on-line to an IBM-PC-compatible computer. Each cage
(43 × 44 × 25 cm) was surrounded with a 15 × 15 array of
photocell beams located 3 cm from the floor surface.
Interruptions of these photocell beams were counted as a mea-
sure of horizontal locomotor activity which was defined as the
traveled distance (cm). Locomotor activity was analyzed
using Auto-Track Software Program (Columbus
Instruments, USA). The horizontal locomotor activity was
measured 30 min after the administration of clonidine
(0.1 mg/kg i.p.) and 60 min after 1MeTIQ (25 mg/kg i.p.)
during 120 min. In the combined group, 1MeTIQ was
administered 30 min before clonidine. Six to eight animals
per group were used.
Biochemical Studies
Ex Vivo: Monoamine Metabolism in Rat Brain Structures
Immediately after the end of the behavioral test (FST), the rats
were killed by decapitation and the brain was rapidly removed
and dissected into different brain structures (frontal cortex,
hypothalamus, and striatum) on an ice-cold glass plate. The
structures were frozen on solid CO2 (−70 °C) until used for
biochemical assays. DA and its metabolites, the intra-neuro-
nal, 3,4-dihydroxyphenylacetic acid (DOPAC); the
extraneuronal, 3-methoxytyramine (3-MT) and final metabo-
lite, homovanillic acid (HVA); and NA and its main
extraneuronal brain metabolite, normetanephrine (NM) and
5-HT and its intra-neuronal metabolite 5-hydroxyindolacetic
acid (5-HIAA) were assayed by means of high-performance
liquid chromatography (HPLC) with electrochemical detec-
tion (ED). The tissue samples were weighted and homoge-
nized in ice-cold 0.1 M trichloroacetic acid containing
0.05 mM ascorbic acid. After centrifugation (10,000×g,
5 min), the supernatants were filtered through RC58 at
0.2 μm cellulose membranes (Bioanalytical Systems, West
Lafayette, IN, USA). The chromatograph HP 1050 (Hewlett-
Packard, Golden, CO, USA) was equipped with Hypersil col-
umn BDS-C18 (4 × 100 mm, 3 μm). The mobile phase
consisted of 0.05 M citrate-phosphate buffer at pH 3.5,
0.1 mM EDTA, 1 mM sodium octyl sulfonate, and 3.5%
methanol. The flow rate was maintained at 1 ml/min. DA,
NA, and 5-HT and their metabolites were quantified by peak
area comparisons with standards run on the day of analysis
(ChemStation, Hewlett-Packard software computer program).
Calculations and Statistics
The results of the behavioral and biochemical studies were
analyzed by a two-way analysis of variance (ANOVA) follow-
edwhen appropriate, by Duncan’s post hoc test. The data were
considered statistically significant when P < 0.05.
The total catabolism rate for dopamine was assessed from
the ratio of the final dopamine metabolite concentration HVA
to dopamine concentration and expressed as the catabolic rate
index (HVA)/(DA) × 100; the index of dopamine release as the
ratio: (3-MT)/(DA) × 100; and the factor of dopamine reup-
take inhibition as the ratio (3-MT)/(DOPAC) × 100.
Analogously, the rate of noradrenaline metabolism was
expressed as the ratio of the extraneuronal metabolite,
normetanephrine to noradrenaline: (NM)/(NA) × 100 and se-
rotonin as the ratio: (5-HIAA)/(5-HT) × 100. The indices were
calculated using concentrations from individual tissue sam-




The Effects of Clonidine and 1MeTIQ in the FST
Clonidine (0.1 mg/kg, i.p.) did not produce pro-depressive
activity in the FST and did not change the immobility time
F(1, 27) = 3.31; P < 0.0987 (Fig. 1a); however, it significantly
enhanced the climbing behavior F(1, 27) = 12.24; P < 0.0016
(Fig. 1c) and slightly decreased the swimming time in rats
(Fig. 1b). 1MeTIQ (25 mg/kg, i.p.) administration produced
antidepressant-like effect and significantly reduced (by 35%;
F(1, 27) = 4.89; P < 0.0487) the immobility time in the FST
(Fig. 1a). The two-way ANOVA showed a significant increase
in the swimming activity after 1MeTIQ (F(1, 27) = 8.16;
P < 0.0081) and no change in the climbing activity (F(1,
27) = 0.16; ns).
Duncan’s post hoc test demonstrated that combined treat-
ment with 1MeTIQ + clonidine significantly increased (by
90%, P < 0.0159) the climbing activity in the FST (Fig. 1c).
The Effect of 1MeTIQ on Clonidine-Produced Depression
in the Locomotor Activity Test
The results of the locomotor activity test showed a significant
inhibitory effect of clonidine (0.1 mg/kg i.p.). The two-way
ANOVA revealed a significant effect of clonidine (F(1,
21) = 15.11; P < 0.0008) and its interaction with 1MeTIQ (F(1,
21) = 5.87; P < 0.0244) in the locomotor activity test. Duncan’s
post hoc test demonstrated that clonidine decreased locomotor
activity by 35% when compared with the saline group
(P < 0.0004). 1MeTIQ alone did not affect (F(1, 21) = 0.18;
ns) the locomotor activity but significantly (P < 0.05) antago-
nized the clonidine-induced depression in rats (Fig. 2).
Neurochemical Studies
The Effect of 1MeTIQ on the Dopamine Metabolism in Rat
Brain Structures in the Clonidine-Produced Model
of Depression
Dopamine The two-way ANOVA indicated a significant ef-
fect of 1MeTIQ treatment on DA concentration only in the
frontal cortex (F(1, 23) = 20.31, P < 0.0001) and no significant
effect of clonidine and interaction of 1MeTIQ + CLO.
Duncan’s post hoc test revealed a significant increase in DA
concentration in the 1MeTIQ-treated group (about 28% of
control saline group, P < 0.05) and in the combined group
1MeTIQ + CLO (about 60% of control, P < 0.01) (Table 1).
Fig. 1 The effect of clonidine, 1MeTIQ, and their combined treatment in
FST. The rats received a single injection of saline (control group);
1MeTIQ (25 mg/kg i.p.) was administered 1 h before clonidine
(0.1 mg/kg i.p.) in the joint group, and 1 h after clonidine
administration, the FST was carried out. The rats were placed into the
cylinder for 5 min, and during this time, three types of behavior were
measured: immobility (a), swimming (b), and climbing (c). The data are
means ± SEM, the number of animals per group (n = 6–8). *P < 0.05
difference from the control group (SAL); +P < 0.05 difference from the
clonidine group with Duncan’s test














Fig. 2 The effect of 1MeTIQ on the clonidine induced a locomotor
depression in rats. The rats received a single injection of saline (control
group), 1MeTIQ (25 mg/kg i.p.), and clonidine (0.1 mg/kg i.p.); in
combined group, 1MeTIQ was administered 30 min before clonidine,
and 30 min after clonidine administration, the rats were placed into
actometers for 120 min. The data are means ± SEM, the number of
animals per group (n = 6–8). *P < 0.05 difference from the control
group (SAL); +P < 0.05 difference from the clonidine group with
Duncan’s test
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Dopac The two-way ANOVA showed a significant effect of
1MeTIQ on DOPAC level in all investigated structures (the
frontal cortex F(1, 23) = 10.54, P < 0.003; hypothalamus F(1,
23) = 31.23, P < 0.000001; striatum F(1, 23) = 57.57,
P < 0.00000) while clonidine affected it only in the hypothal-
amus (F(1, 23) = 5.61, P < 0.0265), and no significant effect of
interaction of these drugs was observed. Duncan’s post hoc
test revealed a significant decrease in DOPAC concentration
after these treatments (from 20 to 40% of the control values),
most strongly pronounced after 1MeTIQ in the hypothalamus
(Table 1).
3-MT The two-way ANOVA demonstrated a significant ef-
fect of 1MeTIQ on the concentration of an extraneuronal
Table 1 Duncan’s post hoc test revealing a significant increase in DA concentration in the 1MeTIQ-treated group and in the combined group
1MeTIQ + CLO
Treatments Number DA (ng/mg prot.) DOPAC (ng/mg prot.) 3-MT (ng/mg prot.) HVA (ng/mg prot.)
T1 T2
Frontal cortex
Saline Saline 6 565 ± 38 118 ± 6.0 16 ± 1.8 136 ± 5.9
Saline CLO/0,1 8 634 ± 56 110 ± 9.1 9 ± 1.2* 125 ± 9.2
1MeTIQ/25 Saline 6 725 ± 63* 90 ± 8.2* 31 ± 2.0** 135 ± 11.2
1MeTIQ/25 CLO/0,1 8 914 ± 31**++ 92 ± 2.8* 29 ± 2.3**++ 152 ± 9.1
Effect of 1MeTIQ F(1, 23) = 20.31 F(1, 23) = 10.54 F(1, 23) = 88.37 F(1, 23) = 1.98
P < 0.0001 P < 0.003 P < 0.0000001 ns
Effect of CLO F(1, 23) = 7.01 F(1, 23) = 0.14 F(1, 23) = 5.79 F(1, 23) = 0.10
P < 0.01 ns P < 0.02 ns
Interaction of 1MeTIQ + CLO F(1, 23) = 1.50 F(1, 23) = 0.41 F(1, 23) = 1.65 F(1, 23) = 2.35
ns ns ns ns
Hypothalamus
Saline Saline 6 549 ± 53 101 ± 11 11 ± 1 66 ± 8
Saline CLO/0,1 8 592 ± 28 81 ± 5* 5 ± 1** 48 ± 6
1MeTIQ/25 Saline 6 620 ± 49 59 ± 8**, ++ 18 ± 1**, ++ 39 ± 6**
1MeTIQ/25 CLO/0,1 8 649 ± 33 45 ± 4**, ++ 13 ± 2++, ^^ 40 ± 5**
Effect of 1MeTIQ F(1, 23) = 2.57 F(1, 23) = 31.23 F(1, 23) = 28.93 F(1, 23) = 7.29
ns P < 0.000011 P < 0.00001 P < 0.012771
Effect of CLO F(1, 23) = 0.79 F(1, 23) = 5.61 F(1, 23) = 15.99 F(1, 23) = 1.56
ns P < 0.026548 P < 0.000564 ns
Interaction of 1MeTIQ + CLO F(1, 23) = 0.029 F(1, 23) = 0.1945 F(1, 23) = 0.06 F(1, 23) = 2.2699
ns ns ns ns
Striatum
Saline Saline 6 10,848 ± 152 1950 ± 63 213 ± 18 883 ± 52
Saline CLO/0,1 8 11,090 ± 293 1853 ± 57 116 ± 14** 759 ± 56
1MeTIQ/25 Saline 6 11,714 ± 452 1398 ± 121** 208 ± 9 726 ± 101
1MeTIQ/25 CLO/0,1 8 11,678 ± 759 1272 ± 83**, ++ 174 ± 23+ 733 ± 69
Effect of 1MeTIQ F(1, 23) = 1.89 F(1, 23) = 57.57 F(1, 23) = 1.97 F(1, 23) = 1.71
ns P < 0.0000001 ns ns
Effect of CLO F(1, 23) = 0.04 F(1, 23) = 3.93 F(1, 23) = 11.99 F(1, 23) = 0.69
ns ns P < 0.002 ns
Interaction of 1MeTIQ + CLO F(1, 23) = 0.07 F(1, 23) = 0.19 F(1, 23) = 2.82 F(1, 23) = 0.88
ns ns ns ns
1MeTIQ in a dose of 25 mg/kg i.p. was administered 30 min before clonidine (0.1 mg/kg i.p.; combined group). The control group received saline.
Animals were decapitated 90 min after clonidine injection. The concentration of dopamine (DA) and its metabolites was expressed as nanograms per
gram of wet tissue. The data are the means ± SEM. The results were analyzed by means of two-way ANOVA analysis of variance, followed when
appropriate, by post hoc Duncan’s test. Statistical significance
*P < 0.05; **P < 0.01 vs. control group; +P < 0.05; ++P < 0.01 vs. clonidine-treated group—statistical significance; ^^P <0.01 vs. 1MeTIQ-treated group
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metabolite of dopamine, 3-MT in the frontal cortex (F(1,
23) = 88.37, P < 0.00000) and hypothalamus (F (1,
23) = 28.93, P < 0.00001) and no significant effect of interac-
tion of 1MeTIQ + CLO. The ANOVA showed also a signif-
icant effect of clonidine on 3-MT in all analyzed structures
(the frontal cortexF(1, 23) = 5.79, P < 0.025; hypothalamusF(1,
23) = 15.99,P < 0.000564; striatumF(1, 23) = 11.99, P < 0.002).
As shown by Duncan’s post hoc test, 1MeTIQ significantly
increased the level of 3-MT in the frontal cortex and hypothal-
amus, in contrast, clonidine significantly decreased its concen-
tration in all structures (Table 1).
HVAThe two-way ANOVA demonstrated a significant effect
of 1MeTIQ only in the hypothalamus (F(1, 23) = 7.29,
P < 0.0127) and no effect of clonidine and the interaction of
1MeTIQ with clonidine in these structures. Duncan’s post hoc
test revealed a significant decrease (P < 0.01) in the HVA level
after treatment with 1MeTIQ alone and as well as in the com-
bined group 1MeTIQ + clonidine (Table 1).
The Indices of Dopamine Catabolism The two-way
ANOVA indicated a significant effect of the treatments:
1MeTIQ, clonidine, and their interaction 1MeTIQ + clonidine
on the rate of total dopamine catabolism (HVA)/(DA). The
effect of 1MeTIQ treatment was significant in all investigated
structures: frontal cortex (F(1, 23) = 6.440, P < 0.010), hypo-
thalamus (F(1, 23) = 23.78, P < 0.00006), and striatum (F(1,
23) = 5.19, P < 0.030), while clonidine showed a significant
effect only in the hypothalamus (F(1, 23) = 5.46, P < 0.028),
and their interaction was significant also in these structures
(F(1, 23) = 5.95, P < 0.022). Duncan’s post hoc test demon-
strated a significant decrease in the rate of total dopamine
metabolism with the same direction after treatment of
1MeTIQ and clonidine (Table 2).
At the same time, the statistical analysis demonstrated a
significant increase in the rate of dopamine release measured
as the ratio of (3-MT)/(DA) after 1MeTIQ treatment in the
frontal cortex and hypothalamus (F(1, 23) = 36.38,
P < 0.000004; F(1, 23) = 17.65, P < 0.000341, respectively),
but opposite effect was observed after clonidine injection, i.e.,
a significant decrease of the rate of dopamine release in all
investigated structures (Table 2).
The two-way ANOVA indicated a significant but opposite
effects of the 1MeTIQ and clonidine treatments on the factor
of dopamine reuptake inhibition calculated as the ratio (3-
MT)/(DOPAC). Duncan’s post hoc test demonstrated its sig-
nificant increase (about 200% of the control value; P < 0.001)
after 1MeTIQ administration but a significant decrease (about
50% of the control value; P < 0.01) after clonidine injection in
rat brain structures which shows the clear inhibitory effect of
1MeTIQ on the dopamine transporter (DAT) expressed with
the index (3-MT)/(DOPAC) (Table 2).
The Effect of 1MeTIQ on Clonidine-Produced Depression
Manifested by Changes in the Metabolism of Noradrenaline
in Rat Brain Structures
Noradrenaline One-way ANOVA revealed a significant ef-
fect of clonidine (F(1, 23) = 20.21, P < 0.0001) in the frontal
cortex and 1MeTIQ in the frontal cortex and striatum (F(1,
23) = 5.62, P < 0.02; F(1, 23) = 6.705, P < 0.01, respectively).
Duncan’s post hoc test indicated a significant increase in the
concentration of noradrenaline after clonidine (by about 28%
of the control group; P < 0.05) and in the combined group
1MeTIQ + clonidine (about 60% of the control group,
P < 0.001) in the frontal cortex as well as in the striatum (about
36% of the control group; P < 0.05) (Table 3).
NM One-way ANOVA demonstrated a significant but oppo-
site effect of 1MeTIQ and clonidine as well as their interaction
in all investigated structures: frontal cortex, hypothalamus,
and striatum. Duncan’s post hoc test indicated that clonidine
led to a significant decrease (from 35 to 50% of the control;
P < 0.05) in NM level in all investigated brain structures.
Also, 1MeTIQ induced an opposite effect to clonidine and
significantly increased the NM level (from 60% of control,
P < 0.05 in the striatum to about 300% of the control,
P < 0.001 in the frontal cortex and hypothalamus) (Table 3).
The Index of Noradrenaline Catabolism Two-way ANOVA
indicated a significant but opposite effects of the treatments:
1MeTIQ and clonidine as well as their interaction 1MeTIQ +
clonidine on the rate of noradrenaline catabolism (NM)/(NA).
The effect of treatment with 1MeTIQ was significant in the
frontal cortex (F(1, 23) = 107.40, P < 0.00000) and hypothala-
mus (F(1, 23) = 109.60, P < 0.00000) and that of clonidine in all
investigated structures: frontal cortex (F(1, 23) = 42.02,
P < 0.00000), hypothalamus (F(1, 23) = 25.24, P < 0.00004),
and striatum (F(1, 23) = 54.094, P < 0.05). Their interaction also
revealed a statistical significance (frontal cortex: F(1,
23) = 17.86, P < 0.0003; hypothalamus: F(1, 23) = 6.52,
P < 0.017; striatum: F(1, 23) = 2.94, P < 0.05). Duncan’s post
hoc test demonstrated a significant decrease (from 40%,
P < 0.05 in the frontal cortex and striatum; about 50%,
P < 0.05 in the hypothalamus) in the rate of noradrenaline
catabolism after clonidine treatment. As opposed to clonidine,
administration of 1MeTIQ led to a strong, significant increase
(about 300%, P < 0.001) in the rate of noradrenaline catabolism
in the frontal cortex and hypothalamus, and a weaker impact in
the striatum (about 27% of control, P < 0.05) (Table 3).
The Effect of 1MeTIQ on Clonidine-Induced Depression
Manifested by Changes in the Serotonin Metabolism
Serotonin One-way ANOVA indicated a significant effect of
treatment with 1MeTIQ on the level of serotonin in all
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investigated structures: frontal cortex, hypothalamus, and stri-
atum (F(1, 23) = 58.87, P < 0.00000; F(1, 23) = 5.53, P < 0.027;
F(1, 23) = 9.89, P < 0.004, respectively) and no effect of clo-
nidine treatment and interaction of 1MeTIQ with clonidine
(Table 4). Duncan’s post hoc test indicated that administration
of 1MeTIQ produced a significant increase in serotonin
concentration in the frontal cortex (about 30% of control,
P < 0.01) and in the hypothalamus (about 17% of control,
P < 0.05) (Table 4).
5-HIAA One-way ANOVA demonstrated a significant effect
of treatments: 1MeTIQ and clonidine on the level of 5-HIAA
Table 2 Duncan’s post hoc test
demonstrating a significant
decrease in the rate of total
dopamine metabolism
Treatments Number (HVA)/(DA) (3-MT)/(DA) (3-MT)/(DOPAC)
T1 T2
Frontal cortex
Saline Saline 6 25 ± 2.5 3 ± 0.3 14 ± 1.5
Saline CLO/0,1 8 20 ± 1.5 1 ± 0.2** 8 ± 1.3*
1MeTIQ/25 Saline 6 19 ± 2.1* 4 ± 0.3** 36 ± 4.2**
1MeTIQ/25 CLO/0,1 8 17 ± 1.2** 3 ± 0.2++ 32 ± 2.2**, ++
Effect of 1MeTIQ F(1, 23) = 6.44 F(1, 23) = 36.38 F(1, 23) = 99.18
P < 0.01 P < 0.000004 P < 0.0000001
Effect of CLO F(1, 23) = 3.59 F(1, 23) = 21.54 F(1, 23) = 4.11
ns P < 0001 P < 0.05
Interaction of 1MeTIQ + CLO F(1, 23) = 0.45 F(1, 23) = 0.06 F(1, 23) = 0.04
ns ns ns
Hypothalamus
Saline Saline 6 12 ± 0.8 2 ± 0.3 11 ± 2
Saline CLO/0,1 8 8 ± 0.9** 1 ± 0.1** 6 ± 0.8*
1MeTIQ/25 Saline 6 6 ± 0.4** 3 ± 0.1**, ++ 31 ± 2**, ++
1MeTIQ/25 CLO/0,1 8 6 ± 0.6** 2 ± 0.3++ 28 ± 4**++
effect of TIQ F(1, 23) = 23.78 F(1, 23) = 17.65 F(1, 23) = 59.00
P < 0.000063 P < 0.000341 P < 0.0000001
Effect of CLO F(1, 23) = 5.46 F(1, 23) = 21.34 F(1, 23) = 4.05
P < 0.028484 P < 0.00012 P < 0.05
interaction of 1Me TIQ + CLO F(1, 23) = 2.95 F(1, 23) = 0.29 F(1, 23) = 0.15
ns ns ns
Striatum
Saline Saline 6 8 ± 0.5 2.0 ± 0.2 11 ± 1.0
Saline CLO/0,1 8 7 ± 0.5 1.0 ± 0.1** 6 ± 0.6*
1MeTIQ/25 Saline 6 6 ± 0.8* 1.8 ± 0.1 15.1 ± 0.8*
1MeTIQ/25 CLO/0,1 8 6 ± 0.5* 1.5 ± 0.2 14 ± 1.5*, ++
Effect of 1MeTIQ F(1, 23) = 5.19 F(1, 23) = 0.70 F(1, 23) = 29.13
P < 0.03 ns P < 0.00001
Effect of CLO F(1, 23) = 1.24 F(1, 23) = 13.62 F(1, 23) = 6.46
ns P < 0.001 P < 0.01
Interaction of 1MeTIQ + CLO F(1, 23) = 1.68 F(1, 23) = 4.08 F(1, 23) = 1.68
ns ns ns
1MeTIQ in a dose of 25 mg/kg i.p. was administered 30 min before clonidine (0.1 mg/kg i.p.; combined group).
The control group received saline. Animals were decapitated 90 min after clonidine injection. The rate of DA
metabolism was expressed as the ratio of its metabolite concentrations to dopamine, (metabolites)/to (DA) × 100.
The indices were calculated using concentrations from individual tissue samples. The data are the means ± SEM.
The results were analyzed by means of two-way ANOVA analysis of variance, followed when appropriate, by
post hoc Duncan’s test
*P < 0.05; **P < 0.01 vs. control group; +P < 0.05; ++ P < 0.01 vs. clonidine-treated group—statistical
significance
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in the tested structures: frontal cortex (F(1, 23) = 50.46,
P < 0.000000; F(1, 23) = 9.50, P < 0.005 respectively), hypo-
thalamus (F(1, 23) = 111.96, P < 0.00000; F(1, 23) = 53.51,
P < 0.000001, respectively), and striatum (F(1, 23) = 10.59,
P < 0.003; F(1, 23) = 7.91, P < 0.009, respectively) and no
significant effect of their co-administration. Duncan’s post
hoc test indicated that both clonidine and 1MeTIQ
significantly decreased the concentration of 5-HIAA in all
investigated brain structures (Table 4).
The Index of Serotonin Catabolism One-way ANOVA re-
vealed a significant effect of treatments: 1MeTIQ and cloni-
dine on the index of serotonin catabolism (5-HIAA)/(5-HT) in
all analyzed structures: frontal cortex (F(1, 23) = 215.43,
Table 3 Duncan’s post hoc test
indicating a significant increase in
the concentration of
noradrenaline after clonidine
Treatment Number NA (ng/mg prot.) NM (ng/mg prot.) (NM)/(NA)
T1 T2
Frontal cortex
Saline Saline 6 168 ± 11 11 ± 0.7 7 ± 0.4
Saline CLO/0,1 8 215 ± 10* 8 ± 0.6* 4 ± 0.3*
1MeTIQ/25 Saline 6 182 ± 5 41 ± 1.8** 22 ± 0.7**
1MeTIQ/25 CLO/0,1 8 274 ± 21**, + 27 ± 2.7**, ++ 11 ± 1.7*, ++
Effect of 1MeTIQ F(1, 23) = 5.62 F(1, 23) = 169.18 F(1, 23) = 107.40
P < 0.02 P < 0.0000001 P < 0.0000001
Effect of CLO F(1, 23) = 20.21 F(1, 23) = 17.68 F(1, 23) = 42.02
P < 0.0001 P < 0.0003 P < 0.000001
Interaction of 1MeTIQ + CLO F(1, 23) = 2.15 F(1, 23) = 8.93 F(1, 23) = 17.86
ns P < 0.006 P < 0.0003
Hypothalamus
Saline Saline 6 1194 ± 62 13 ± 0,8 1.2 ± 0.12
Saline CLO/0,1 8 1407 ± 101 7 ± 0,9* 0.5 ± 0.05*
1MeTIQ/25 Saline 6 1366 ± 103 55 ± 3**, ++ 4.0 ± 0.3**, ++
1MeTIQ/25 CLO/0,1 8 1475 ± 141 32 ± 3**, ++ 2.1 ± 0.3**, ++
Effect of 1MeTIQ F(1, 23) = 1.075 F(1, 23) = 226.4815 F(1, 23) = 109.6038
ns P < 0.0000001 P < 0.0000001
Effect of CLO F(1, 23) = 1.9194 F(1, 23) = 40.6956 F(1, 23) = 25.2442
ns P < 0.000002 P < 0.000044
Interaction of 1MeTIQ + CLO F(1, 23) = 0.1971 F(1, 23) = 15.0388 F(1, 23) = 6.5234
ns P < 0.0007 P < 0.0177
Striatum
Saline Saline 6 29 ± 7 8 ± 0.8 26 ± 5
Saline CLO/0,1 8 31 ± 5 5 ± 0.6* 16 ± 7*
1MeTIQ/25 Saline 6 41 ± 7* 14 ± 1.3*, + 33 ± 5*, +
1MeTIQ/25 CLO/0,1 8 40 ± 5* 11 ± 1.6 28 ± 3+
Effect of 1MeTIQ F(1, 23) = 6.705 F(1, 23) = 12.162 F(1, 23) = 0.141
P < 0.01 P < 0.001 ns
Effect of CLO F(1, 23) = 0.370 F(1, 23) = 4.312 F(1, 23) = 4.094
ns P < 0.041 P < 0.050
Interaction of 1MeTIQ + CLO F(1, 23) = 0.180 F(1, 23) = 2.232 F(1, 23) = 2.945
ns ns P = 0.050
1MeTIQ in a dose of 25 mg/kg i.p. was administered 30 min before clonidine (0.1 mg/kg i.p.; combined group).
The control group received saline. Animals were decapitated 90 min after clonidine injection. The concentration
of noradrenaline (NA) and its metabolite normetanephrine (NM) was expressed as nanograms per gram of wet
tissue. The rate of NA metabolism was expressed as the ratio of its metabolite concentration to noradrenaline,
(NM)/to (NA) × 100. The data are the means ± SEM. The results were analyzed by means of two-way ANOVA
analysis of variance, followed when appropriate, by post hoc Duncan’s test
*P < 0.05; **P < 0.01 vs. control group; +P < 0.05; ++ P < 0.01 vs. clonidine-treated group—statistical
significance
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P < 0.000000; F(1, 23) = 36.95, P < 0.000003, respectively),
hypothalamus (F(1, 23) = 120.29, P < 0.00000; F(1, 23) = 38.51,
P < 0.000002, respectively), and striatum (F(1, 23) = 67.72,
P < 0.000000; F(1, 23) = 8.51, P < 0.007, respectively) and
no significant effect of their co-administration on the index of
serotonin catabolism (Table 4).
Discussion
Depression is a multicausal disorder which affects up to 25%
of the worldwide population (Maes 2008). For the last two
decades, the monoaminergic hypothesis of depression had
been thought to explain the dominant cause of depression,
Table 4 One-way ANOVA
indicating a significant effect of
treatment with 1MeTIQ on the
level of serotonin in all
investigated structures
Treatment Number 5-HT (ng/mg prot.) 5-HIAA (ng/mg prot.) (5-HIAA)/(5-HT)
T1 T2
Frontal cortex
Saline Saline 6 522 ± 21 156 ± 6.9 30 ± 0.5
Saline CLO/0,1 8 578 ± 14 131 ± 4.6** 23 ± 0.6**
1MeTIQ/25 Saline 5 678 ± 17** 109 ± 6.8** 17 ± 1.1**
1MeTIQ/25 CLO/0,1 8 765 ± 28**, ++ 103 ± 3.9**, ++ 13 ± 0.8**, ++
Effect of 1MeTIQ F(1, 23) = 58.87 F(1, 23) = 50.46 F(1, 23) = 215.43
P < 0.0000001 P < 0.0000001 P < 0.0000001
Effect of CLO F(1, 23) = 3.22 F(1, 23) = 9.50 F(1, 23) = 36.95
ns P < 0.005 P < 0.000003
Interaction of 1MeTIQ +
CLO
F(1, 23) = 2.55 F(1, 23) = 2.17 F(1, 23) = 2.58
ns ns ns
Hypothalamus
Saline Saline 6 924 ± 33 239 ± 11 26 ± 0.3
Saline CLO/0,1 8 967 ± 40 188 ± 6** 20 ± 1**
1MeTIQ/25 Saline 5 1074 ± 59* 163 ± 10**, + 15 ± 1**, ++
1MeTIQ/25 CLO/0,1 8 1019 ± 37 100 ± 5**, ++ 10 ± 1**, ++
Effect of 1MeTIQ F(1, 23) = 5.536 F(1, 23) = 111.96 F(1, 23) = 120.294
P < 0.02755 P < 0.0000001 P < 0.0000001
Effect of CLO F(1, 23) = 0.019 F(1, 23) = 53.517 F(1, 23) = 38.516
ns P < 0.000001 P < 0.000002
Interaction of 1MeTIQ +
CLO
F(1, 23) = 1.306 F(1, 23) = 0.615 F(1, 23) = 0.176
ns ns ns
Striatum
Saline Saline 6 405 ± 32 332 ± 20 83 ± 3.4
Saline CLO/0,1 8 385 ± 9 290 ± 10* 75 ± 1.8*
1MeTIQ/25 Saline 5 456 ± 13 283 ± 18* 62 ± 2.8**
1MeTIQ/25 CLO/0,1 8 444 ± 11+ 244 ± 11**, + 55 ± 2.1**, ++
Effect of 1MeTIQ F(1, 23) = 9.89 F(1, 23) = 10.59 F(1, 23) = 67.72
P < 0.004 P < 0.003 P < 0.0000001
Effect of CLO F(1, 23) = 0.820 F(1, 23) = 7.91 F(1, 23) = 8.51
ns P < 0.009 P < 0.007
Interaction of 1MeTIQ +
CLO
F(1, 23) = 0.05 F(1, 23) = 0.02 F(1, 23) = 0.02
ns ns ns
1MeTIQ in a dose of 25 mg/kg i.p. was administered 30 min before clonidine (0.1 mg/kg i.p.; combined group).
The control group received saline. Animals were decapitated 90 min after clonidine injection. The concentration
of serotonin (5-HT) and its metabolite, 5-hydroxyindolacetic acid (5-HIAA) was expressed as nanograms per
gram of wet tissue. The rate of 5-HT metabolism was expressed as the ratio of its metabolite concentration to
serotonin, (5-HIAA)/to (5-HT) × 100. The indices were calculated using concentrations from individual tissue
samples. The data are the means ± SEM. The results were analyzed by means of two-way ANOVA analysis of
variance, followed when appropriate, by post hoc Duncan’s test
*P < 0.05; **P < 0.01 vs. control group; +P < 0.05; ++ P < 0.01 vs. clonidine-treated group—statistical
significance
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and generally, antidepressant agents were produced based on
this hypothesis. The MAO inhibitors, although not used as
extensively as some other antidepressants, have an important
role in the treatment of atypical depression and depression
associated with anxiety, agitation, and phobia. However, other
strategies beyond serotonin and noradrenaline reuptake inhi-
bition such as anti-oxidant and anti-inflammatory agents may
represent promising antidepressant therapeutics, which was
already demonstrated by researchers in animal models of de-
pression (Lopresti et al. 2012; Lang and Borgwardt 2013).
Additionally, it should be taken into account that some natural
compounds with antidepressant potential (e.g., curcumin), al-
though their mechanism of the antidepressant activity is not
fully understood, have been hypothesized to act through
inhibiting the MAO enzyme and modulating the release of
5-HT and DA (Kulkarni et al. 2009). Similarly, the distur-
bances in the function of vesicular monoamine transporter 2
(VMAT2) in the cytosol which is responsible for the accumu-
lation of biogenic amines in presynaptic stores may be the
cause of the molecular processes which produce neurotoxicity
and underlying depression disease (Miller et al. 1999).
1MeTIQ, an endogenous compound present in the mam-
malian brain exerts a distinct antidepressant-like effect in
some animal models of depression (FST, reserpine model of
depression) as it was previously demonstrated by us
(Antkiewicz-Michaluk et al. 2014b; Możdżeń et al. 2014;
Wąsik et al. 2013). What is interesting is that 1MeTIQ pos-
sesses antidepressant-like activity both in the behavioral as
well as in neurochemical s tudies . General ly, i ts
antidepressant-like effect was associated with the complex
mechanism of action in the CNS. 1MeTIQ activates monoam-
inergic systems, elevates the concentrations of dopamine, nor-
adrenaline, and serotonin in the brain structures as a reversible
MAO inhibitor, and acts as a scavenger of free radicals.
In the present paper, we used clonidine as a useful and well-
known animal model of depression (Enginar and Eroglu, 1990;
Parale and Kulkarni 1986; Park et al. 2016) to investigate the
antidepressant-like effect of 1MeTIQ. Clonidine is an alpha2
adrenoceptor agonist used in clinical practice in the therapy of
hypertension; however, depression is known to be a side effect
of clonidine treatment. Similarly, the induction of depression-
like behavior in rats using clonidine was well documented (Dyr
et al. 2009; Enginar and Eroglu 1990; Kostowski and
Obersztyn 1988; Parale and Kulkarni 1986). In the present
study, we demonstrated the antidepressant potential of
1MeTIQ in the clonidine model of depression. To begin the
behavioral tests, it was demonstrated that clonidine used in a
low dose (0.1 mg/kg i.p.) produced a distinct inhibitory effect
on the locomotor activity, which was significantly antagonized
by 1MeTIQ administration (Fig. 2). On the other hand, another
behavioral test, i.e., the FST used in the present study indicated
that clonidine did not change the antidepressant-like effect of
1MeTIQ connected with the direct shortening of the
immobility time of rats; however, it completely prevented the
1MeTIQ-induced changes in the swimming behavior (Fig. 1a,
B). In the joint treatment group (clonidine + 1MeTIQ), a sig-
nificant higher climbing behavior was observed (Fig. 1c).What
does it mean that in the FST, clonidine completely antagonized
1MeTIQ-induced swimming behavior? We suggest that such
effect can be explained by the different mechanisms of action
of clonidine and 1MeTIQ in relation to motivational processes.
The FST is a behavioral test used to predict the efficacy of
antidepressant treatments (Porsolt et al. 1977). It has a good
predictive value for antidepressant potency in humans (Wilner
1984). The modified FST measures the frequency of different
types of active behaviors: swimming, which is sensitive to
serotoninergic compounds, such as specific serotonin reuptake
inhibitors (SSRIs), and climbing, which is sensitive to tricyclic
antidepressants and drugs with selective effects on catechol-
amine transmission (Cryan and Lucki 2000; Cryan et al.
2005; Detke et al. 1995, 1996). As shown by Detke et al.
(1995, 1996), the increase in climbing activity is connected
with an enhanced noradrenaline system activation. In that case,
clonidine as an alpha2 adrenoreceptor agonist inhibits the ac-
tivity of noradrenergic neurons and should break the climbing
behavior. Such discrepancies in the clonidine mechanism of
action can be connected with the function of the postsynaptic
alpha2 adrenoceptors in the spinal cord which plays an essential
role in locomotion. In fact, Giroux et al. (2001) demonstrated in
the intact and spinal cuts that noradrenaline-descending system
played a crucial role in the control of locomotion since stimu-
lation of the noradrenergic postsynaptic alpha2 receptor by clo-
nidine in the spinal cord prolonged the cycle duration and in-
creased the amplitude of flexor and extensor bursts. In contrast,
blockade of alpha2 receptor by intrathecal injection of yohim-
bine, its antagonist, resulted in a marked disruption of walking
(Chau et al. 1998; Giroux et al. 2001). Clonidine may exert an
effect primarily on interneurons that coordinate the timing be-
tween flexor and extensor muscle (Chau et al. 1998). In the
light of these findings, it is possible that stimulation of the
postsynaptic spinal noradrenergic alpha2 receptor by clonidine
may be responsible for the increase in the climbing behavior
observed in the FST.
We should also take into account that clonidine as an ago-
nist of the presynaptic alpha2 noradrenergic receptors inhibits
noradrenergic neurons in the locus coeruleus (LC)
(Aghajanian and Vandermaelen 1982). In fact, the data from
experimental animals suggested that all effective
antidepressant drugs as well as electroconvulsive shock
caused a decrease in the activity of LC neurons, the major
noradrenaline-containing cell bodies (Grant and Weiss 2001;
Bourin et al. 2002). Additionally, clonidine in low dose po-
tentiated the anti-immobility effects of antidepressants in the
FST in mice (Bourin et al. 2002; Zeidan et al. 2007).
It should be underlined that, except for the FST, oth-
er behavioral test (for example, locomotor activity test)
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and particularly biochemical studies (the inhibition of
monoamine metabolism in the brain structures) indicate
the Bpro-depressive-like^ effects produced by clonidine
administration. It is well documented that monoamine
neurotransmitters are involved in the pathogenesis of
depression and play an important role in mediating the
effects of antidepressants (Javaid et al. 1979; Borsini
and Meli 1988). Both clinical and experimental data
agree on the fact that classical antidepressants (imipra-
mine and desipramine) as well as SSRI and SNRI acti-
vate monoaminergic neurotransmission in the brain
(Grunewald et al. 1979; Javaid et al. 1979; Borsini
and Meli 1988; Borsini 1995; Cryan and Lucki 2000;
Cryan et al. 2005; Detke et al. 1995). Neurochemical
data in the present paper demonstrated that clonidine
produced a significant inhibition of monoamine neurons.
The release of dopamine, noradrenaline, and serotonin
as well as the rate of their metabolism was diminished
in the investigated brain structures (frontal cortex,
hypothalamus, and striatum; Tables 1, 2, 3, and 4).
The indices presented in the paper such as (3-MT)/
(DA), (3-MT)/(DOPAC), (NM)/(NA), and (5-HIAA)/(5-
HT) have shown a distinct reduction of the activity of
monoaminergic neurons in all investigated brain struc-
tures. 1MeTIQ which demonstrated a significant
antidepressant-like effect in the FST completely antago-
nized clonidine-induced depression of monoaminergic
systems and restored their function.
Based on comparison of the results of behavioral and
biochemical experiments, we suggest that noradrenergic
alpha2 receptors in the brain and in the spinal cord are
different. It seems that spinal postsynaptic alpha2 recep-
tors in contrast to brain presynaptic alpha2 receptors are
not connected with the motivation function. In fact,
1MeTIQ did not antagonize the effect of clonidine on
the climbing behavior in the FST but completely antag-
onized the clonidine-induced depression in the locomo-
tor activity test as well as the reduction of brain mono-
aminergic neuron activity.
It should be mentioned that 1MeTIQ is characterized by a
wide spectrum of actions on all monoaminergic systems in rat
brain. Thanks to its ability to inhibit both MAO A and B
activities and to scavenge free radicals, 1MeTIQ possesses a
neuroprotective activity (Patsenka and Antkiewicz-Michaluk
2004; Antkiewicz-Michaluk et al. 2006). These results justify
the question about the physiological significance of endoge-
nous tetrahydroisoquinoline in the control of neurotransmitter
function and prevention of neurotoxicity related to MAO ac-
tivity in the brain. We would like to suggest that 1MeTIQmay
be useful not only for the therapy of neurodegenerative dis-
eases (e.g., PD) but also in the treatment of depression as a
new antidepressant which can markedly reduce the side-effect
profile.
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